Eversept Partners LP increased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 24.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,434,725 shares of the biopharmaceutical company’s stock after purchasing an additional 280,805 shares during the period. Celldex Therapeutics accounts for about 2.0% of Eversept Partners LP’s investment portfolio, making the stock its 13th biggest holding. Eversept Partners LP’s holdings in Celldex Therapeutics were worth $38,967,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of CLDX. Aster Capital Management DIFC Ltd acquired a new position in Celldex Therapeutics in the third quarter worth about $26,000. Wilmington Savings Fund Society FSB acquired a new position in Celldex Therapeutics in the third quarter worth about $42,000. Russell Investments Group Ltd. boosted its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares during the period. Quantbot Technologies LP acquired a new position in Celldex Therapeutics in the third quarter valued at approximately $63,000. Finally, Kestra Advisory Services LLC acquired a new position in Celldex Therapeutics in the fourth quarter valued at approximately $98,000.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on CLDX shares. Stifel Nicolaus restated a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. UBS Group lifted their target price on Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. The Goldman Sachs Group lifted their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research note on Monday, March 2nd. Wells Fargo & Company lifted their target price on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Finally, Barclays lifted their target price on Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $49.30.
Celldex Therapeutics Trading Up 1.9%
Shares of NASDAQ CLDX opened at $32.93 on Thursday. Celldex Therapeutics, Inc. has a 12-month low of $19.52 and a 12-month high of $35.79. The company has a market cap of $2.58 billion, a PE ratio of -7.73 and a beta of 0.95. The stock has a 50 day simple moving average of $31.96 and a 200-day simple moving average of $28.97.
Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.80 million. Sell-side analysts forecast that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current fiscal year.
Celldex Therapeutics Profile
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.
Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.
Read More
- Five stocks we like better than Celldex Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
